Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic ...

Dental pulp injury caused by trauma or deep caries often leads to inflammation, tissue necrosis, and eventual loss of tooth ...

Keros Therapeutics KROS is focused on developing and commercializing novel therapeutics to treat a wide range of patients ...

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 and TGF-beta, as a treatment for advanced gastric cancer. The green light – ...

Dental pulp injury caused by trauma or deep caries often leads to inflammation, tissue necrosis, and eventual loss of tooth vitality. In severe cases ...

A growing body of research points to chronic, low-grade inflammation inside the brain as a possible accelerant of Alzheimer’s disease, not just a bystander response to damage already done. The 2024 ...

Dental pulp regeneration remains a major clinical challenge. Researchers have discovered that SMAD7 directly forms a ...

Bicara Therapeutics (NASDAQ:BCAX) outlined its clinical and development strategy for its lead bifunctional antibody program, FICERA, during a presentation and fireside chat at TD Cowen’s 46th annual ...

NOVEL heart failure (HF) research has identified a surprising protective signal produced directly by heart muscle cells that may help slow the development of cardiac fibrosis, a key driver of ...

Within contemporary molecular biology, the regulation of tissue growth has emerged as a central theme linking developmental signaling, metabolic balance, and structural adaptation. Among the molecular ...

A new 3D model shows that Duchenne gene therapy can repair muscle fibers but fails to shut down the signals that drive scarring.